Mirum Pharmaceuticals Inc (MIRM)vsNovartis AG ADR (NVS)
MIRM
Mirum Pharmaceuticals Inc
$93.72
+0.19%
HEALTHCARE · Cap: $5.61B
NVS
Novartis AG ADR
$161.93
+0.38%
HEALTHCARE · Cap: $303.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 9181% more annual revenue ($57.36B vs $618.07M). NVS leads profitability with a 17.5% profit margin vs -139.2%. NVS earns a higher WallStSmart Score of 48/100 (D+).
MIRM
Avoid30
out of 100
Grade: F
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+45.4%
Fair Value
$182.99
Current Price
$93.72
$89.27 discount
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$161.93
$66.37 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37.9% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
ROE of -329.4% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MIRM
The strongest argument for MIRM centers on Revenue Growth, Debt/Equity. Revenue growth of 37.9% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bear Case : MIRM
The primary concerns for MIRM are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
MIRM profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
MIRM carries more volatility with a beta of 0.61 — expect wider price swings.
MIRM is growing revenue faster at 37.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 30/100), backed by strong 17.5% margins. MIRM offers better value entry with a 45.4% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mirum Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?